Literature DB >> 23107067

Pathological outcome and biochemical recurrence-free survival after radical prostatectomy in African-American, Afro-Caribbean (Jamaican) and Caucasian-American men: an international comparison.

Chad R Ritch1, Belinda F Morrison, Greg Hruby, Kathleen C Coard, Richard Mayhew, William Aiken, Mitchell C Benson, James M McKiernan.   

Abstract

OBJECTIVE: To compare pathological and biochemical outcomes of radical prostatectomy (RP) among African-American (AA), Afro-Caribbean (AC; Jamaican) and Caucasian-American (CA) men using an international cohort of patients who underwent RP in the USA and Jamaica.
MATERIALS AND METHODS: A retrospective review was performed of men who underwent RP for clinically organ-confined (OC) prostate cancer between 2000 and 2011 at Columbia University Medical Center (New York, USA) and the University Hospital of the West Indies (Kingston, Jamaica) between 2000 and 2007. Men who had received neoadjuvant or adjuvant (within 3 months) therapy were excluded. Clinicopathological variables were compared among the three groups, focusing on age, stage, PSA level, Gleason sum (GS) and margin status. Multivariate analysis was performed to determine the predictors of biochemical recurrence (BCR; PSA >0.2 ng/mL), and Kaplan-Meier analysis was performed to determine BCR-free survival rates in AA, AC and CA men.
RESULTS: A total of 483 men underwent RP for clinically OC disease (CM, n = 309, AA, n = 93 and AC, n = 81). The mean patient age was 59 years, with AA men being younger than CA men (58 vs 60 years, P< 0.05). The mean (range) follow-up was 49 (13-133) months with no significant difference among the groups. The men in the AC cohort had a higher mean PSA level than AA and CA men (8.8 vs 6.2 and 5.0 ng/mL, respectively, P< 0.05) and more clinical GS ≥7 (44%) tumours than AA (8%) and CA men (0%; P< 0.01). On multivariate analysis, controlling for stage, grade, PSA level and margins, AA and AC race were independent predictors of BCR. AA and AC men had significantly lower 5-year BCR-free survival (76 and 74%, respectively) than CA men (98% [P < 0.001]).
CONCLUSIONS: This international comparison of clinicopathological outcomes in AA, AC and CA men undergoing RP shows that AA and AC men present similarly with more aggressive disease features than CA men and have lower 5-year BCR-free survival. Both AA and AC race are significant predictors of BCR, independently of stage, grade, PSA level and margin status. Further research is needed to elucidate and correct the mechanisms behind the observed difference in outcome among these populations.
© 2012 THE AUTHORS. BJU INTERNATIONAL © 2012 BJU INTERNATIONAL.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23107067     DOI: 10.1111/j.1464-410X.2012.11540.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  18 in total

1.  Pathological and Biochemical Outcomes among African-American and Caucasian Men with Low Risk Prostate Cancer in the SEARCH Database: Implications for Active Surveillance Candidacy.

Authors:  Michael S Leapman; Stephen J Freedland; William J Aronson; Christopher J Kane; Martha K Terris; Kelly Walker; Christopher L Amling; Peter R Carroll; Matthew R Cooperberg
Journal:  J Urol       Date:  2016-06-25       Impact factor: 7.450

Review 2.  Prostate cancer in men of African origin.

Authors:  Kathleen F McGinley; Kae Jack Tay; Judd W Moul
Journal:  Nat Rev Urol       Date:  2015-12-31       Impact factor: 14.432

3.  Preoperative prognostic factors for biochemical recurrence after robot-assisted radical prostatectomy in Japan.

Authors:  Takeshi Hashimoto; Kunihiko Yoshioka; Tatsuo Gondo; Choichiro Ozu; Yutaka Horiguchi; Kazunori Namiki; Yoshio Ohno; Makoto Ohori; Jun Nakashima; Masaaki Tachibana
Journal:  Int J Clin Oncol       Date:  2013-09-19       Impact factor: 3.402

4.  Comparison of oncologic outcomes after radical prostatectomy in men diagnosed with prostate cancer with PSA levels below and above 4 ng/mL.

Authors:  Charles Dariane; Chloé Le Cossec; Sarah J Drouin; Benoit Wolff; Benjamin Granger; Pierre Mozer; Marc-Olivier Bitker; Shahrokh F Shariat; Olivier Cussenot; Morgan Rouprêt
Journal:  World J Urol       Date:  2013-04-26       Impact factor: 4.226

5.  Impact of race in a predominantly African-American population of patients with low/intermediate risk prostate cancer undergoing radical prostatectomy within an equal access care institution.

Authors:  David Schreiber; Eric B Levy; David Schwartz; Justin Rineer; Andrew Wong; Marvin Rotman; Jeffrey P Weiss
Journal:  Int Urol Nephrol       Date:  2014-06-27       Impact factor: 2.370

6.  Pathological examination of radical prostatectomy specimens in men with very low risk disease at biopsy reveals distinct zonal distribution of cancer in black American men.

Authors:  Debasish Sundi; Oleksandr N Kryvenko; H Ballentine Carter; Ashley E Ross; Jonathan I Epstein; Edward M Schaeffer
Journal:  J Urol       Date:  2013-06-14       Impact factor: 7.450

7.  African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them?

Authors:  Debasish Sundi; Ashley E Ross; Elizabeth B Humphreys; Misop Han; Alan W Partin; H Ballentine Carter; Edward M Schaeffer
Journal:  J Clin Oncol       Date:  2013-06-17       Impact factor: 44.544

8.  Racial and socioeconomic disparities in presentation and outcomes of well-differentiated thyroid cancer.

Authors:  Avital Harari; Ning Li; Michael W Yeh
Journal:  J Clin Endocrinol Metab       Date:  2013-12-20       Impact factor: 5.958

9.  Analysis of Prostate Cancer Susceptibility Variants in South African Men: Replicating Associations on Chromosomes 8q24 and 10q11.

Authors:  Pedro Fernandez; Muneeb Salie; Danielle du Toit; Andre van der Merwe
Journal:  Prostate Cancer       Date:  2015-08-12

10.  Rural-urban differences in the clinico-pathologic profiles of Jamaican men with prostate cancer.

Authors:  William D Aiken; Kieron S Jones; Camille Ragin; Kenneth James
Journal:  Infect Agent Cancer       Date:  2015-09-28       Impact factor: 2.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.